Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

Rhea-AI Summary

Kodiak Sciences (Nasdaq: KOD) will present final Phase 1b APEX clinical results for KSI-101 in macular edema secondary to inflammation (MESI) at the virtual Angiogenesis meeting on February 7, 2026.

Dr. Sumit Sharma will present Week 24 end-of-study data at 5:15 PM ET; the presentation will be posted in the company's Events and Presentations section. The company says the final data show robust anatomic and visual improvements and continue to support the safety profile of KSI-101 while Phase 3 PEAK and PINNACLE studies remain actively enrolling.

News Market Reaction – KOD

-6.87%

-6.87% Session close to close

In the Feb 4 session, KOD declined 6.87%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -6.9% in the session following this news. A negative reaction despite positive comme...

Analysis

The stock moved -6.9% in the session following this news. A negative reaction despite positive commentary on APEX end-of-study data would fit a history where encouraging clinical updates sometimes coincided with mild selling, such as the -1.49% move after strong Week 20 MESI data. With multiple late-stage programs in play, sentiment may have been sensitive to trial-risk perceptions. Large downside moves could reflect profit-taking or broader risk-off behavior rather than a specific data failure.

Key Figures

Week 24 data: Week 24 Phase 1b: Phase 1b Presentation time: 5:15 PM EST

3 metrics

Week 24 data Week 24 End-of-study APEX Phase 1b MESI results presented

Phase 1b Phase 1b APEX study stage for KSI-101 in MESI

Presentation time 5:15 PM EST Scheduled Angiogenesis 2026 presentation of APEX results

Previous Clinical trial Reports

3 past events · Latest: Nov 05 (Positive)

Same Type Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
Nov 05	APEX Week 20 data	Positive	-1.5%	Week 20 APEX data showing strong fluid resolution and vision gains in MESI.
Sep 15	APEX clinical update	Positive	+1.1%	New APEX data showing >50% achieving ≥15-letter gains and rapid drying.
May 13	GLOW2 trial initiation	Positive	+0.3%	First patients treated in Phase 3 GLOW2 after strong GLOW1 DR results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical trial updates have produced modest stock reactions, with a mix of small gains and one mild selloff despite generally positive data.

Recent Company History

Recent history for Kodiak centers on retinal clinical progress. Prior APEX updates for KSI-101 in MESI on Sep 15, 2025 and Nov 5, 2025 highlighted strong vision gains and retinal drying, yet share moves stayed modest (from -1.49% to +1.08%). Earlier, on May 13, 2024, initiation of the Phase 3 GLOW2 study for tarcocimab in diabetic retinopathy also saw only a small reaction. Today’s end-of-study APEX results continue this pattern of steady clinical strengthening rather than dramatic trading shifts.

Key Terms

macular edema, uveitis, bispecific trap-antibody, interleukin-6, +2 more

6 terms

macular edema medical

"Phase 1b APEX study in patients with macular edema secondary to inflammation (MESI)."

Macular edema is a buildup of fluid in the macula, the small central part of the eye responsible for sharp, straight-ahead vision, which causes blurred or distorted sight as if looking through a smudged camera lens. For investors it matters because the condition drives demand for treatments, influences clinical trial results and regulatory approvals, and can change a company’s sales and valuation when new drugs or devices prove effective or fail.

uveitis medical

"Dr. Sumit Sharma, retina and uveitis specialist at the Cole Eye Institute, will present"

Uveitis is inflammation inside the eye that can damage tissues responsible for clear vision, causing pain, light sensitivity, blurred sight, or permanent vision loss if untreated. For investors, it matters because it represents a medical condition with significant unmet need and chronic treatment requirements, influencing the size of potential drug or device markets, clinical trial design and endpoints, regulatory hurdles, and long-term revenue prospects — similar to how chronic engine trouble signals ongoing repair and maintenance demand.

bispecific trap-antibody medical

"Bispecific Trap-antibody Inhibiting Interleukin-6 and Vascular Endothelial Growth Factor (KSI-101)"

A bispecific trap-antibody is an engineered therapeutic protein with two different binding arms that act like a double-headed hook to grab and neutralize two separate disease-related molecules at once, or to hold them in a way that prevents harmful signaling. For investors, this matters because the approach can boost effectiveness or reduce side effects compared with single-target drugs, so clinical results, safety data and regulatory progress can strongly influence a drug candidate’s commercial prospects.

interleukin-6 medical

"Bispecific Trap-antibody Inhibiting Interleukin-6 and Vascular Endothelial Growth Factor (KSI-101)"

Interleukin-6 is a small signaling protein the body releases to coordinate inflammation and immune responses, acting like a fire alarm that summons immune cells to sites of infection or tissue damage. It matters to investors because high or persistent levels are linked to disease activity and are a common drug target or clinical trial biomarker; changes in IL-6-related data can influence a therapy's approval prospects, market potential, and a company's valuation.

vascular endothelial growth factor medical

"Bispecific Trap-antibody Inhibiting Interleukin-6 and Vascular Endothelial Growth Factor (KSI-101)"

Vascular endothelial growth factor (VEGF) is a naturally occurring protein that signals the body to grow new blood vessels—think of it like a fertilizer for blood vessels. It matters to investors because many drugs either block or mimic VEGF to treat conditions such as cancers and certain eye diseases; clinical trial outcomes, regulatory approvals, or safety issues tied to VEGF-targeting therapies can materially affect a company’s revenue prospects and stock value.

phase 1b medical

"Week 24 data, from the Phase 1b APEX study in patients with macular edema"

"Phase 1b" is an early stage in testing a new medical treatment or vaccine, where it is given to a small group of people to evaluate its safety and determine the right dose. For investors, this phase signals progress in development, indicating the treatment is advancing through initial safety checks, which can influence expectations for future success and potential market impact.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PALO ALTO, Calif., Feb. 4, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today participation at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration) annual meeting on February 7, 2026.

Dr. Sumit Sharma, retina and uveitis specialist at the Cole Eye Institute, will present first-time end-of-study clinical results, including Week 24 data, from the Phase 1b APEX study in patients with macular edema secondary to inflammation (MESI).

• Presentation title: Bispecific Trap-antibody Inhibiting Interleukin-6 and Vascular Endothelial Growth Factor (KSI-101): Phase 1b APEX Study in Patients with Macular Edema Secondary to Inflammation (MESI)
• Time: 5:15 PM EST

The presentation will be posted at the start of the event on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/.

"This year's Angiogenesis meeting marks the first presentation of end-of-study results from the APEX study for KSI-101. These final data continue to demonstrate robust anatomic and visual improvements in patients with MESI, regardless of the underlying etiology or location of inflammation, further supporting the clinical efficacy and safety profile of KSI-101 observed to date. With PEAK and PINNACLE Phase 3 studies actively enrolling, these final results strengthen our confidence in KSI-101's potential to become a safe, first-line unifying therapy for all causes of MESI," said Victor Perlroth, M.D., Chairman and CEO of Kodiak Sciences.    

About KSI-101

KSI-101 is a novel, potent and high strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF. We are developing KSI-101 for patients with macular edema (retinal fluid) secondary to inflammation (MESI). MESI is a heterogenous group of diseases that clinically present with macular edema and visual impairment which are caused by a common pathophysiology–inflammation and blood retinal barrier disruption. The clinical presentation of retinal fluid and visual impairment is a mainstay in these patients, irrespective of the location of the inflammation inside of the eye (anterior, intermediate, posterior or all intraocular compartments) or the specific etiology (defined autoimmune associated, idiopathic, post-procedural, or inflammatory choroidal neovascularization).

Currently there are no available intravitreal biologic therapies addressing the spectrum of MESI diseases. We believe that MESI represents a new market segment separate from the established anti-VEGF market.

We have completed enrollment in our dose-finding Phase 1b study APEX. The APEX study evaluates KSI-101 in two cohorts, Cohort 1 in patients with diabetic macular edema (DME) and Cohort 2 in patients with macular edema secondary to inflammation (MESI). APEX demonstrated that KSI-101 provides meaningful visual and anatomical gains in both DME and MESI and that KSI-101 is well tolerated. Meaningful treatment responses were seen in the MESI population, irrespective of the location of inflammation and specific MESI etiology, opening up the potential for KSI-101 to become a unifying treatment for this patient population.

Based on APEX, the top two dose levels tested were selected to advance into the Phase 3 program. The PEAK and PINNACLE Phase 3 studies are actively enrolling MESI subjects at the 5 mg and 10 mg dose levels versus sham.

About Kodiak Sciences Inc.

Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. We are developing a portfolio of three late-stage clinical programs. Tarcocimab and KSI-501 are being explored in two BLA-facing Phase 3 studies in the retinal vascular diseases, targeting the $15 billion anti-VEGF marketplace, with topline data readouts expected in 1Q 2026 and 3Q 2026. KSI-101 is a bispecific protein being explored in two BLA-facing Phase 3 studies in Macular Edema Secondary to Inflammation (MESI), with topline data readouts expected in 4Q 2026 (PEAK) and 2Q 2027 (PINNACLE).

Kodiak^®, Kodiak Sciences^®, ABC^®, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding Kodiak's plans, commitments, aspirations and goals related to Kodiak's drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled "Risk Factors" in Kodiak's most recent periodic report filed with the U.S. Securities and Exchange Commission ("SEC") as well as discussions of potential risks, uncertainties, and other important factors in Kodiak's subsequent filings with the SEC. All information in this press release is as of the date presented, and Kodiak undertakes no duty to update such information unless required by law.

View original content:https://www.prnewswire.com/news-releases/final-apex-phase-1b-clinical-results-for-kodiaks-ksi-101-in-macular-edema-secondary-to-inflammation-to-be-presented-at-angiogenesis-2026-302678453.html

SOURCE Kodiak Sciences Inc.

FAQ

What Phase 1b APEX results will Kodiak (KOD) present at Angiogenesis on February 7, 2026?

Kodiak will present end-of-study Week 24 results from the Phase 1b APEX study of KSI-101 in MESI. According to the company, the data show robust anatomic and visual improvements and continued support for the drug's safety profile.

Who is presenting Kodiak's (KOD) APEX Week 24 data and when is the presentation?

Dr. Sumit Sharma will present the APEX Week 24 data on February 7, 2026 at 5:15 PM ET. According to the company, the presentation will be posted at the start of the event in Kodiak's Events and Presentations section online.

What is KSI-101 and what targets does it inhibit as described by Kodiak (KOD)?

KSI-101 is described as a bispecific trap-antibody inhibiting interleukin-6 and vascular endothelial growth factor. According to the company, this dual-target mechanism underpins the APEX study evaluation in macular edema secondary to inflammation.

How do Kodiak (KOD) say the APEX final data affect KSI-101's clinical progress and Phase 3 plans?

Kodiak says the final APEX data strengthen confidence in KSI-101 as a potential first-line unifying therapy for MESI. According to the company, PEAK and PINNACLE Phase 3 studies are actively enrolling to further evaluate the drug.

Where can investors access Kodiak's (KOD) Angiogenesis 2026 presentation and supporting materials?

The presentation will be posted at the start of the event in Kodiak's Events and Presentations section on its investor website. According to the company, the material will be accessible via the specified investor relations web page.